替奈普酶后静脉替罗非班治疗急性缺血性卒中:INSTANT随机临床试验
INSTANT试验在中国37家医院随机双盲安慰剂对照纳入359例急性缺血性卒中患者,均无大中血管闭塞或心源性栓塞病因,且在替奈普酶输注后4-24小时内系列NIHSS评估显示临床反应不足(无显著变化、神经功能恶化或波动)。替罗非班组177例接受0.3 μg/kg/min负荷30分钟继以0.075 μg/kg/min持续输注最长47.5小时,安慰剂组182例;主要终点90天极佳预后(mRS 0-1分)替罗非班组63.8% vs 安慰剂组52.2%(RR 1.22,95%CI 1.02-1.46,P=0.03)。48小时内症状性颅内出血替罗非班组1例(0.9%)vs 安慰剂组0例,90天死亡率0.6% vs 1.6%。
要点
- 替罗非班组90天极佳预后(mRS 0-1)63.8% vs 安慰剂组52.2%,RR 1.22(95%CI 1.02-1.46,P=0.03)。
- 适用人群:急性缺血性卒中、无大中血管闭塞或心源性栓塞病因、替奈普酶后4-24小时内NIHSS系列评估显示临床反应不足。
- 替罗非班方案:0.3 μg/kg/min静脉负荷30分钟,继以0.075 μg/kg/min持续输注最长47.5小时,替奈普酶后4-24小时内启动。
- 口服抗血小板(阿司匹林和/或氯吡格雷)在安慰剂组溶栓后24小时、替罗非班组溶栓后44小时启动,全部患者持续至90天随访。
- 48小时内症状性颅内出血替罗非班组1例(0.9%)vs 安慰剂组0例;90天死亡率0.6% vs 1.6%。
适用人群与场景
- 急性缺血性卒中患者,无大或中等血管闭塞,无心脏栓塞性病因。
- 静脉替奈普酶输注后4-24小时内系列NIHSS评估显示临床反应不足,定义为较基线无显著变化、神经功能恶化或神经功能波动。
- 研究在中国37家医院进行,随机359例,平均年龄66岁,女性141例(39.3%)。
诊断标准与关键阈值
- 临床反应不足定义:替奈普酶输注后4-24小时内系列NIHSS评分评估显示较基线无显著变化、神经功能恶化或神经功能波动。
- 主要终点极佳预后定义:90天改良Rankin量表评分0或1分(量表范围0-6分,评分越高残疾越重)。
处置流程与药物剂量
- 替罗非班组:静脉替罗非班0.3 μg/kg/min负荷输注30分钟,继以0.075 μg/kg/min持续输注最长47.5小时,于替奈普酶后4-24小时内启动。
- 安慰剂组:匹配安慰剂。
- 口服抗血小板治疗(阿司匹林和/或氯吡格雷):安慰剂组于溶栓后24小时启动,替罗非班组于溶栓后44小时启动,全部患者持续至90天随访。
红旗征与不能漏的情况
- 48小时内症状性颅内出血:替罗非班组1例(0.9%),安慰剂组0例。
- 90天死亡:替罗非班组0.6%,安慰剂组1.6%。
研究设计与关键结果
- 研究类型:研究者发起的随机、双盲、安慰剂对照试验,中国37家医院,纳入359例,358例(99.7%)完成试验。
- 主要终点:90天极佳预后(mRS 0-1分)替罗非班组113例(63.8%)vs 安慰剂组95例(52.2%),RR 1.22(95%CI 1.02-1.46,P=0.03)。
- 安全性:48小时内症状性颅内出血替罗非班组1例(0.9%)vs 安慰剂组0例;90天死亡率替罗非班组0.6% vs 安慰剂组1.6%。
- 招募时间2024年4月24日至2025年7月16日,最终随访2025年10月11日。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于无大中血管闭塞或心源性栓塞、替奈普酶后4-24小时内临床反应不足的急性缺血性卒中患者,辅助静脉替罗非班可提高90天极佳预后可能性(作者结论)。
- 替罗非班方案为0.3 μg/kg/min负荷30分钟继以0.075 μg/kg/min输注最长47.5小时,替奈普酶后4-24小时内启动;口服抗血小板在替罗非班组溶栓后44小时启动。
- 该人群需排除大中血管闭塞和心源性栓塞病因,且需在替奈普酶后4-24小时内通过系列NIHSS评估确认临床反应不足。
指南或共识出处
- INSTANT随机临床试验(NCT05604638),发表于JAMA。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Although recent trials have shown benefit with early tirofiban after thrombolysis, its efficacy remains uncertain in patients with acute ischemic stroke who do not have a large or medium vessel occlusion or a cardioembolic source and who show an inadequate clinical response to intravenous tenecteplase.
OBJECTIVE: To assess the efficacy and safety of intravenous tirofiban administered after an inadequate response to intravenous tenecteplase in this specific patient population.
DESIGN, SETTING, AND PARTICIPANTS: Investigator-initiated, randomized, double-blind, placebo-controlled trial conducted at 37 hospitals in China, enrolling 359 patients with acute ischemic stroke, without large or medium vessel occlusion or cardioembolic etiology, and with an insufficient clinical response to intravenous tenecteplase (defined as no significant change from baseline, neurological deterioration, or neurological fluctuation based on serial assessment of the National Institutes of Health Stroke Scale score within 4-24 hours after infusion). Recruitment took place between April 24, 2024, and July 16, 2025, with final follow-up on October 11, 2025.
INTERVENTIONS: Intravenous tirofiban (n = 177), administered as a 0.3-μg/kg/min bolus over 30 minutes, followed by a continuous infusion of 0.075 μg/kg/min for up to 47.5 hours, or matching placebo (n = 182), initiated within 4 to 24 hours after intravenous tenecteplase. Oral antiplatelet therapy (aspirin and/or clopidogrel) was started 24 hours after thrombolysis in the placebo group and 44 hours after thrombolysis in the tirofiban group and continued in all patients through 90-day follow-up.
MAIN OUTCOMES AND MEASURES: The primary outcome was an excellent outcome (defined as a score of 0 or 1 on the modified Rankin Scale; range, 0-6, with higher scores indicating more severe disability) at 90 days. Safety outcomes included incidence of symptomatic intracranial hemorrhage within 48 hours and 90-day mortality.
RESULTS: Among 359 patients randomized (mean age, 66 years; 141 females [39.3%]), 358 (99.7%) completed the trial. An excellent outcome at 90 days was observed in 113 patients (63.8%) in the tirofiban group and in 95 patients (52.2%) in the placebo group (risk ratio, 1.22; 95% CI, 1.02-1.46; P = .03). Symptomatic intracranial hemorrhage within 48 hours occurred in 1 patient (0.9%) in the tirofiban group and no patients in the placebo group; 90-day mortality was 0.6% and 1.6%, respectively.
CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke without large or medium vessel occlusion or a cardioembolic source who had an inadequate clinical response to intravenous tenecteplase, adjunctive intravenous tirofiban increased the likelihood of an excellent outcome at 90 days.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05604638.
参考来源
- Liu X, Zhang F, Zhang C, et al. Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial. JAMA. 2026. PMID: 42100960. doi:10.1001/jama.2026.5245
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。